1. Ann Oncol. 2023 Nov;34(11):962-963. doi: 10.1016/j.annonc.2023.10.002.

Time to start testing KRAS and BRAF V600E mutations in stage III colon cancer? 
Not in routine care, yet in clinical trials.

Dienstmann R(1).

Author information:
(1)Oncoclínicas Precision Medicine and Big Data, Oncoclínicas, São Paulo, 
Brazil; Vall d'Hebron Institute of Oncology, Barcelona, Spain; University of Vic 
- Central University of Catalonia. Electronic address: rdienstmann@vhio.net.

DOI: 10.1016/j.annonc.2023.10.002
PMID: 37996169 [Indexed for MEDLINE]